Latest News

Takeda presenta los resultados del ensayo de fase 3 ALTA-1L que destaca la eficacia intracraneal de ALUNBRIG® (brigatinib) en comparación con crizotinib en el cáncer de pulmón amicrocítico ALK+ avanzado de primera línea


CAMBRIDGE, Massachusetts y OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) ha anunciado hoy que los datos de eficacia intracraneal del ensayo de fase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st L [Ensayo del cáncer de pulmón ALK de brigatinib en primera línea] ha demostrado una mejoría en la supervivencia libre de progresión (SLP) intracraneal y en la tasa de respuesta objetiva (TRO) intracraneal con ALUNBRIG (brigatinib), en comparación con crizoti

Source link

Related posts

Less access to specialists associated with higher death, hospitalization rates among rural patients

Newsemia

Scientists learn what women know—and don't know—about breast density and cancer risk

Newsemia

The coronavirus sneaks into cells through a key receptor. Could targeting it lead to a treatment?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World